Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | PLG | P00747 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | THRB | P10828 | 1/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.39 |
| ▸ | RECQL | P46063 | 1/20 | 0.39 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.39 |
| ▸ | PAOX | Q6QHF9 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.36 |
| ▸ | BLM | P54132 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15773249 | 1.00 | KMT2A (0.39) | KMT2AALDH1A1MEN1PLGLMNA | |
| SCHEMBL26198454 | 1.00 | KMT2A (0.39) | KMT2AALDH1A1MEN1PLGLMNA | |
| Bromide SCHEMBL5681816 | 0.98 | KMT2A (0.38) | KMT2AALDH1A1MEN1PLGLMNA | |
| SCHEMBL18768942 | 0.98 | CYP2D6 (0.38) | KMT2AALDH1A1MEN1PLGLMNA | |
| SCHEMBL8829865 | 0.93 | CYP1A2 (0.41) | KMT2ALMNATHRBSMN1; SMN2CYP2D6 | |
| SCHEMBL13192974 | 0.91 | SLC6A5 (0.39) | KMT2AALDH1A1MEN1PLGLMNA | |
| SCHEMBL905722 | 0.91 | SMN1; SMN2 (0.42) | KMT2AALDH1A1SMN1; SMN2HPGDHTT | |
| SCHEMBL4960230 | 0.91 | SMN1; SMN2 (0.42) | KMT2AALDH1A1SMN1; SMN2HPGDHTT | |
| SCHEMBL379163 | 0.91 | SMN1; SMN2 (0.42) | KMT2AALDH1A1SMN1; SMN2HPGDHTT | |
| SCHEMBL1870550 | 0.91 | SMN1; SMN2 (0.42) | KMT2AALDH1A1SMN1; SMN2HPGDHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 132 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5998616-A | Biocatalyst for the conversion of carbonyl compounds to their β-unsaturated derivatives using molecular oxygen as the oxidant | THE UNIVERSITY OF MICHIGAN (US) | 1999-12-07 | — | — | US | claimed |
| CN-112263682-B | PCSK 9-targeting antisense oligomers and conjugates | 罗氏创新中心哥本哈根有限公司 | 2024-08-20 | — | — | CN | disclosed |
| EP-4357463-A2 | APPLICATION OF EPIGENETIC CHROMSOMAL INTERACTIONS IN CANCER DIAGNOSTICS | Oxford BioDynamics PLC (GB) | 2024-04-24 | — | — | EP | disclosed |
| EP-3704274-B1 | GENETIC REGULATION OF IMMUNORESPONSE BY CHROMOSOME INTERACTIONS | Oxford BioDynamics PLC (GB) | 2024-04-17 | — | — | EP | disclosed |
| EP-3548633-B1 | APPLICATION OF EPIGENETIC CHROMSOMAL INTERACTIONS IN CANCER DIAGNOSTICS | Oxford BioDynamics PLC (GB) | 2024-01-24 | — | — | EP | disclosed |
| EP-4301874-A1 | CHROMOSOME INTERACTION MARKERS | Oxford BioDynamics PLC (GB) | 2024-01-10 | — | — | EP | disclosed |
| EP-4274910-A1 | CHROMOSOME INTERACTIONS | Oxford BioDynamics PLC (GB) | 2023-11-15 | — | — | EP | disclosed |
| US-20230279476-A1 | NOVEL ACRYLATE DERIVATIVES AND USES THEREOF | EXPANSION TECHNOLOGIES (US) | 2023-09-07 | — | — | US | disclosed |
| US-20230279476-A1 | NOVEL ACRYLATE DERIVATIVES AND USES THEREOF | EXPANSION TECHNOLOGIES (US) | 2023-09-07 | — | — | US | disclosed |
| EP-3452612-B1 | DETECTION OF CHROMOSOME INTERACTION RELEVANT TO BREAST CANCER | Oxford BioDynamics PLC (GB) | 2023-08-23 | — | — | EP | disclosed |
| WO-1999038014-A1 | ASSESSING RISK FOR INTEGRIN ANTAGONIST/AGONIST MEDIATED DISEASES | DU PONT PHARMACEUTICALS COMPANY (US) | 1999-07-29 | — | — | WO | disclosed |
| EP-0882233-A1 | METHOD AND DEVICE FOR TREATMENT BY COMPLEXING OF A LIQUID MEDIUM | BIO MERIEUX (FR) | 1998-12-09 | — | — | EP | disclosed |
| WO-1998051435-A1 | FULLY-COATED, UNIFORM-SIZED METALLIC PARTICLES | TANG WEIXIN (US) | 1998-11-19 | — | — | WO | disclosed |
| WO-1998028436-A1 | SCREENING ASSAY FOR PROTEOLYSIS INHIBITORS | ZENECA LIMITED (GB) | 1998-07-02 | — | — | WO | disclosed |
| WO-1998015832-A1 | METHOD AND DEVICE FOR TREATMENT BY COMPLEXING OF A LIQUID MEDIUM | BIO MERIEUX (FR) | 1998-04-16 | — | — | WO | disclosed |
| EP-0525821-A2 | Methods and structures employing non-radioactive chemically-labeled polynucleotide probes | ENZO BIOCHEM, INC. (US) | 1993-02-03 | — | — | EP | disclosed |
| WO-1992003732-A2 | COMPOSITIONS AND METHODS FOR ENHANCED BINDING IN BIOLOGICAL ASSAYS | BIOPROBE INTERNATIONAL, INC. (US) | 1992-03-05 | — | — | WO | disclosed |
| EP-0330221-A2 | End labeled nuceotide probe | ENZO BIOCHEM, INC. (US) | 1989-08-30 | — | — | EP | disclosed |
| WO-1989002933-A1 | NON-NUCLEOTIDE REAGENTS FOR SUBSTITUTING TERMINI OF OLIGONUCLEOTIDES | ML TECHNOLOGY VENTURES, L.P. (US) | 1989-04-06 | — | — | WO | disclosed |
| EP-0310312-A2 | Non-nucleotide reagents for substituting termini of oligonucleotides | M.L. TECHNOLOGY VENTURES, L.P. (US) | 1989-04-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230279476-A1 | NOVEL ACRYLATE DERIVATIVES AND USES THEREOF | DCLRE1A, ACR, PHAX | KMT2A 3464/4885ALDH1A1 2377/4885MEN1 4026/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.